{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Non-nucleoside+reverse+transcriptase+inhibitor+%28NRTIs%29", "query": { "intervention": "Non-nucleoside reverse transcriptase inhibitor (NRTIs)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Non-nucleoside+reverse+transcriptase+inhibitor+%28NRTIs%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T02:56:15.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02422797", "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG 50 mg", "type": "DRUG" }, { "name": "RPV 25 mg", "type": "DRUG" }, { "name": "CAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2015-04-21", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 13, "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422797" }, { "nct_id": "NCT01866267", "title": "Switching Undetectables to Selzentry", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus", "AIDS" ], "interventions": [ { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Hope Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2013-01", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 1, "location_summary": "Bellaire, Texas", "locations": [ { "city": "Bellaire", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01866267" }, { "nct_id": "NCT02938520", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "ABC/DTG/3TC STR - Tablet", "type": "DRUG" }, { "name": "DTG Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2016-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938520" }, { "nct_id": "NCT00440271", "title": "SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "tipranavir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "Optimized Background Regimen (OBR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2007-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 16, "location_summary": "Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440271" }, { "nct_id": "NCT00110305", "title": "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "TMC278 25 mg", "type": "DRUG" }, { "name": "TMC278 75 mg", "type": "DRUG" }, { "name": "TMC278 150 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Non-nucleoside reverse transcriptase inhibitor (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2005-06", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-06-25", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 9, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110305" }, { "nct_id": "NCT00028067", "title": "A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 500, "start_date": "2001-08", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2011-05-04", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 47, "location_summary": "Little Rock, Arkansas • Berkeley, California • Fountain Valley, California + 37 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028067" }, { "nct_id": "NCT03739996", "title": "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Oral Cabotegravir (CAB)", "type": "DRUG" }, { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Long-Acting Injectable Cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC) ART", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2019-12-31", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739996" }, { "nct_id": "NCT00870363", "title": "A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)", "type": "DRUG" }, { "name": "maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)", "type": "DRUG" }, { "name": "efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 44, "start_date": "2009-04", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00870363" }, { "nct_id": "NCT01363011", "title": "Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2011-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-02", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363011" }, { "nct_id": "NCT01903031", "title": "Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Nuvaring", "type": "DEVICE" }, { "name": "EFV", "type": "DRUG" }, { "name": "ATV/r", "type": "DRUG" }, { "name": "TDF", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 84, "start_date": "2014-12-30", "completion_date": "2016-10-10", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-09-26T02:56:15.672Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903031" } ] }